Andrei M. Mikheev
Fred Hutchinson Cancer Research Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrei M. Mikheev.
Breast Cancer Research and Treatment | 2004
Andrei M. Mikheev; Akira Inoue; Lichen Jing; Svetlana A. Mikheeva; Vivian Li; Tomas Leanderson; Helmut Zarbl
We previously identified a positive transcriptional element identical to human Ha-ras response element (HRE) within the promoter of the rat Ha-ras gene. We further identified CArG binding factor A (CBF-A), a member of heterogeneous nuclear ribonuclear protein (hnRNP) gene family, as a trans-acting factor that binds the HRE sequence with high affinity in rat mammary carcinoma cells. To determine if activation of CBF-A plays a role in tumor development in vivo, we investigated CBF-A expression and binding activity in rat mammary tumors induced by N-methyl-N-nitrosourea. We found that ~82% of tumors expressed CBF-A at levels that were 3-20 fold higher than detected in normal mammary gland. Moreover, elevated CBF-A protein levels were invariably associated with increased binding activity to the HRE. CBF-A mRNA levels in tumors were on average elevated only two fold as compared to normal mammary gland, indicating that increased CBF-A protein levels in tumors resulted from both translational and/or post-translational regulation. The level of CBF-A expression in mammary tumors was independent of Ha-ras mutational status. Together, these findings indicated that deregulation of CBF-A contributes to mammary carcinogenesis via a mechanism that is distinct from its hnRNP functions in binding and post-transcriptional regulation of RNA.
PLOS ONE | 2013
Xuefeng Ren; Jessica C. Graham; Lichen Jing; Andrei M. Mikheev; Yuan Gao; Jenny Pan Lew; Hong Xie; Andrea S. Kim; Xiuling Shang; Cynthia Friedman; Graham Vail; Mingzhu Fang; Yana Bromberg; Helmut Zarbl
Rat strains differ dramatically in their susceptibility to mammary carcinogenesis. On the assumption that susceptibility genes are conserved across mammalian species and hence inform human carcinogenesis, numerous investigators have used genetic linkage studies in rats to identify genes responsible for differential susceptibility to carcinogenesis. Using a genetic backcross between the resistant Copenhagen (Cop) and susceptible Fischer 344 (F344) strains, we mapped a novel mammary carcinoma susceptibility (Mcs30) locus to the centromeric region on chromosome 12 (LOD score of ∼8.6 at the D12Rat59 marker). The Mcs30 locus comprises approximately 12 Mbp on the long arm of rat RNO12 whose synteny is conserved on human chromosome 13q12 to 13q13. After analyzing numerous genes comprising this locus, we identified Fry, the rat ortholog of the furry gene of Drosophila melanogaster, as a candidate Mcs gene. We cloned and determined the complete nucleotide sequence of the 13 kbp Fry mRNA. Sequence analysis indicated that the Fry gene was highly conserved across evolution, with 90% similarity of the predicted amino acid sequence among eutherian mammals. Comparison of the Fry sequence in the Cop and F344 strains identified two non-synonymous single nucleotide polymorphisms (SNPs), one of which creates a putative, de novo phosphorylation site. Further analysis showed that the expression of the Fry gene is reduced in a majority of rat mammary tumors. Our results also suggested that FRY activity was reduced in human breast carcinoma cell lines as a result of reduced levels or mutation. This study is the first to identify the Fry gene as a candidate Mcs gene. Our data suggest that the SNPs within the Fry gene contribute to the genetic susceptibility of the F344 rat strain to mammary carcinogenesis. These results provide the foundation for analyzing the role of the human FRY gene in cancer susceptibility and progression.
Nature Genetics | 2001
Helmut Zarbl; Andrei M. Mikheev; Robert C. Sullivan
Patterns of gene expression in mammary cells following carcinogen exposure of strains of rat sensitive or resistant to carcinogenesis
Carcinogenesis | 2004
Andrei M. Mikheev; Svetlana A. Mikheeva; Binrong Liu; Pinchas Cohen; Helmut Zarbl
Cancer Research | 1996
Han Mo Koo; Anne Monks; Andrei M. Mikheev; Larry Rubinstein; Marcia Gray-Goodrich; Mary Jane McWilliams; W. Gregory Alvord; Herbert K. Oie; Adi F. Gazdar; Kenneth D. Paull; Helmut Zarbl; George F. Vande Woude
Nucleic Acids Research | 2000
Andrei M. Mikheev; Svetlana A. Mikheev; Yanni Zhang; Ruedi Aebersold; Helmut Zarbl
Cell Growth & Differentiation | 1999
Maria Athanassiou; Yanwen Hu; Lichen Jing; Benoit Houle; Helmut Zarbl; Andrei M. Mikheev
Carcinogenesis | 2008
Xuefeng Ren; Xun Zhang; Andrea S. Kim; Andrei M. Mikheev; Mingzhu Fang; Robert C. Sullivan; Roger E. Bumgarner; Helmut Zarbl
Archive | 2015
D. Molkentin; Roger R. Markwald; Andrei V. Tkatchenko; Tatiana V. Tkatchenko; Ricardo A. Moreno-Rodriguez; Simon J. Conway; Robert C. Rostomily; Rob G. Oxford; Yoshito Kosai; Kathleen R. Tozer-Fink; Thomas C. Manning; Carolina Parada; Donald E. Born; Barbara Carnemolla; Sam Frankel; Andrei M. Mikheev; Svetlana A. Mikheeva; Andrew D. Trister; Mari J. Tokita
Archive | 2015
Gerald A. Merrill; Phillip D. Bowman; Hong-Khanh B. Dinh; Baiteng Zhao; Steven T. Schuschereba; Gregory S. Schultz; David W. Mozingo; Robert J. Feezor; Heather N. Paddock; Henry V. Baker; Juan C. Varela; Joyce Barreda; L Lyle; Kathleen F. Kerr; Philip E. Mirkes; Svetlana A. Mikheeva; Marianne Barrier; Sally A. Little; Richard P. Beyer; Andrei M. Mikheev; Peter R. Edsall; Bruce E. Stuck